Association of Risk of Suicide Attempts With Methylphenidate Treatment

Kenneth K. C. Man, MPH; David Coghill, MD; Esther W. Chan, PhD; Wallis C. Y. Lau, BSc; Chris Hollis, PhD; Elizabeth Liddle, PhD; Tobias Banaschewski, MD; Suzanne McCarthy, PhD; Antje Neubert, PhD; Kapil Sayal, PhD; Patrick Ip, MBBS; Martijn J. Schuemie, PhD; Miriam C. J. M. Sturkenboom, PhD; Edmund Sonuga-Barke, PhD; Jan Buitelaar, MD; Sara Carucci, MD; Alessandro Zuddas, MD; Hanna Kovshoff, PhD; Peter Garas, MD; Peter Nagy, MD; Sarah K. Inglis, PhD; Kerstin Konrad, PhD; Alexander Häge, MD; Eric Rosenthal, MD; Ian C. K. Wong, PhD

Importance  Patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are the most common treatment for ADHD, but the association between their therapeutic use and suicide is unclear.

Objective  To investigate the association between methylphenidate and the risk of suicide attempts.

Design, Setting, and Participants  A population-based, electronic medical records database from the Hong Kong Clinical Data Analysis & Reporting System was used to identify 25,629 individuals aged 6 to 25 years who were treated with methylphenidate between January 1, 2001, and December 31, 2015. Those who had attempted suicide were included in the analysis. A self-controlled case series design was used to control for time-invariant characteristics of the patients.

Main Outcomes and Measures  Relative incidence of suicide attempt during periods when patients were exposed to methylphenidate compared with nonexposed periods.

Results  Among 25,629 patients with methylphenidate prescriptions, 154 had their first recorded suicide attempt within the study period; of these individuals, 111 (72.1%) were male; mean (SD) age at baseline was 7.15 (2.19) years. The overall incidence of suicide attempts during methylphenidate treatment was 9.27 per 10,000 patient-years. An increased risk of suicide attempts was detected during the 90-day period before methylphenidate was initiated, with an incidence rate ratio (IRR) of 6.55 (95% CI, 3.37-12.72). The IRR remained elevated during the first 90 days of treatment (IRR, 3.91; 95% CI, 1.62-9.42) before returning to baseline levels during ongoing treatment (IRR, 1.35; 95% CI, 0.77-2.38). When the risk during the first 90 days of treatment was compared with the 90 days preceding first treatment, the incidence of suicide attempts was not elevated (IRR, 0.78; 95% CI, 0.26-2.35).

Conclusions and Relevance  The incidence of suicide attempts was higher in the period immediately before the start of methylphenidate treatment. The risk remained elevated immediately after the start of methylphenidate treatment and returned to baseline levels during continuation of methylphenidate treatment. The observed higher risk of suicide attempts before treatment may reflect emerging psychiatric symptoms that trigger medical consultations that result in a decision to begin ADHD treatment. Therefore, this study’s results do not support a causal association between methylphenidate treatment and suicide attempts.
Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder in children, with worldwide prevalence rates in school-aged children estimated at 5% to 7%. In Hong Kong (HK), the reported prevalence of ADHD is estimated to be 6.1% in schoolboys and 3.9% in early adolescents. Attention-deficit/hyperactivity disorder is associated with a diverse range of mental health comorbidities and adverse health, academic, and psychosocial outcomes. Individuals with ADHD are at increased risk of both attempted and completed suicide, even if comorbid psychiatric disorders are clinically treated.

National guidelines recommend psychostimulant medication for the treatment of ADHD. During the past 2 decades, the rate of medication use for ADHD has risen rapidly worldwide. The prevalence of ADHD medication use in HK is approximately 1% in school-aged children and adolescents and has increased 14-fold over the past decade. Methylphenidate hydrochloride, in particular, is commonly used as the first-line therapy. In 2009, the European Medicines Agency conducted a review of the safety of methylphenidate. The review concluded that further research on the association between methylphenidate and psychiatric adverse effects, including suicide risk, was needed.

Although there has been some concern about a potential association between methylphenidate and suicide-related events, few studies have addressed this issue directly. One Swedish register-based study investigated the risk of suicidal behavior among individuals receiving methylphenidate and other stimulants. When comparing treated and nontreated patients with ADHD, this study found that methylphenidate or other stimulant use was associated with a 31% increase in the rate of suicide-related events. However, this analysis did not adjust for potential confounding factors that may account for this association. For instance, a recent study on suicide in school-aged children and adolescents showed that ADHD was overrepresented in suicide victims. Previous studies have also suggested that comorbid disorders and familial/social factors may all play important roles in the association between ADHD and suicide. In a follow-up analysis in the abovementioned register study, when periods with and without treatment were compared within the same patient, no increased risk of suicide-related events during the treatment periods was found. Therefore, at present, there is still uncertainty around the potential effects of methylphenidate on the suicidal behavior of patients. Hence, the aim of the present study was to examine the association between methylphenidate and the risk of suicide attempts.

### Methods

#### Data Source

This study used data from the Clinical Data Analysis & Reporting System (CDARS), an electronic health record database developed by the HK Hospital Authority, a statutory body that manages all public hospitals and their ambulatory clinics in HK. The service is available to all HK residents (>7.3 million) and covers approximately 80% of all hospital admissions in HK.

Data from CDARS have been validated and used for various investigations of medication safety. Patient-specific data in CDARS include diagnosis, prescription, information on hospital admissions and discharges, payment method, and prescription and dispensing information. CDARS contains inpatient, outpatient, and emergency department admissions records, anonymized to protect patient confidentiality. The study protocol was approved by the institutional review board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.

#### Self-controlled Case Series Design

We used the self-controlled case series (SCCS) study design to investigate the association between methylphenidate and suicide attempts. In this design, used previously to investigate the effects of methylphenidate on trauma and psychosis risk, patients serve as their own control. The SCCS design relies on within-person comparisons in a population of individuals who have experienced both the outcome and exposure of interest. Incidence rate ratios (IRRs) are derived by comparing the rate of events during periods of medication exposure with the rate during all other observed time periods (ie, without medication). A major advantage of this design over the classic design is that it controls for potential effects of measured and unmeasured time-invariant confounders that vary between individuals (ie, genetic factors, disease severity, and socioeconomic factors). Furthermore, we adjusted for time-varying factors, such as age and season, which are known to affect methylphenidate treatment prescribing. In addition to the standard SCCS analysis, the nonparametric SCCS approach was applied to investigate risk changes during the observation period.

#### Case Identification

Individuals aged 6 to 25 years who received at least 1 prescription for methylphenidate and who had made at least 1 suicide attempt during the study period (January 1, 2001, to December 31, 2015) were identified in CDARS. The suicide attempt codes were identified through the *International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)* diagnostic codes E950 to E959. The statistical modeling of the SCCS analysis requires incident cases to fulfill the criteria of being exposed to methylphenidate and having at least 1 suicide attempt during the observation period. The exposure to methylphenidate was defined as being exposed to methylphenidate if there was at least 1 prescription for methylphenidate during the observation period.

#### Key Points

**Question** Is treatment with methylphenidate associated with an increased risk of suicide attempts?

**Findings** In this population-based, case series study of 154 patients with a suicide attempt identified from 25 629 patients who were receiving methylphenidate for treatment of attention-deficit/hyperactivity disorder, the risk of suicide attempts was 6.5-fold higher during the 90-day period before methylphenidate was initiated, remained elevated 4-fold during the first 90 days of treatment, and returned to baseline levels during ongoing treatment.

**Meaning** The increased risk of suicide attempts preceding the initiation of methylphenidate is not causally related to the drug’s effects.

© 2017 American Medical Association. All rights reserved.
model assumption; therefore, patients who had made a suicide attempt before the study period were excluded. Only methylphenidate and atomoxetine are licensed for the treatment of ADHD in HK; therefore, the observation periods were censored by atomoxetine treatment to avoid coprescribing situations that could affect comparisons.

We commenced follow-up at age 6 years, as methylphenidate is not recommended for younger children. There has been an increasing trend of methylphenidate use in college-aged young adults up to age 25 years. Observation periods began on January 1, 2001, or the sixth birthday of the patient (whichever was later) and ended on December 31, 2015, the 26th birthday of the patient, date of receiving atomoxetine treatment, or date of registered death (whichever was earlier). Because the aim of this study was to investigate the association between methylphenidate and suicide attempts, all methylphenidate users, regardless of the presence of a formal diagnosis of ADHD, were included.

**Exposures and Outcomes**

For each included participant, all methylphenidate prescriptions and suicide attempts were identified. All methylphenidate formulations (standard and extended release) and all strengths were included in the analysis. Exposed periods were defined as time receiving medication, with the duration between prescription start and end dates recorded in CDARS for each prescription. More than 99% of the prescriptions had the intended start and end dates as recorded in our data set. Daily dosages and the quantity prescribed were used to determine the duration of treatment if the prescription end date was not available. Median values for exposure duration were imputed when the above information was missing. We divided patient time into 4 discrete categories: absence of methylphenidate (baseline period, including patient-time before and after methylphenidate exposure), 90 days before the first methylphenidate exposure (pre-exposure period), first 90 days of methylphenidate use, and subsequent methylphenidate use. We did not assume that participants received continuous treatment on initiation of methylphenidate, because clinicians may offer drug holidays to patients with ADHD during school holidays and treatment may be stopped and started for various other reasons. The pre-exposure period was defined as the time before the first methylphenidate prescription; thus, there were no pre-exposure periods before the second or subsequent methylphenidate treatments. The study design and timeline for a single hypothetical participant are given in Figure 1. The corresponding date of a suicide attempt was identified as an event date, and only the first recorded suicide attempt for each patient was included in the analysis. In SCCS designs, there should be no censoring by the outcome of interest, as this would violate their assumption and invalidate the results. We conducted a validation analysis by reviewing the information in CDARS. Through doing this, we identified that, in 153 of 154 (99.4%) cases, the ICD-9-CM diagnosis code of a suicide attempt was confirmed in the medical records by an emergency department clinician, hospital pediatrician, and/or psychiatrist. Consequently, the risk of misclassification is considered to be low.

**Statistical Analysis**

The association between methylphenidate treatment and suicide attempts was calculated by comparing the rate of suicide attempts during exposure periods with that during baseline periods. Adjusted IRR and the corresponding 95% CIs were calculated using conditional Poisson regression, adjusted for age in 1-year bands and season. A 90-day pre-exposure period was added to take account of the possibility that the suicide attempt may affect the likelihood of methylphenidate treatment, which in turn may introduce bias into the risk estimate during treatment. We separated the first 90 days of methylphenidate use to allow the detection of any temporary change in the IRR of suicide attempts, and we also compared the rate of suicide attempts between the pre-exposure period and the methylphenidate-exposed periods. To investigate whether emergent psychiatric disorders could lead to methylphenidate treatment, post hoc analyses were conducted, using the same setting as the original analysis, to test the association between methylphenidate treatment and other psychiatric conditions (ICD-9-CM codes 290-319). A significance level of 5% was used in all statistical analyses. SAS, version 9.4 (SAS Institute Inc) and R, version 3.3.1 (http://www.R-project.org) were used for data manipulation and analysis.

**Sensitivity Analyses**

Sensitivity analyses were planned to test the validity and robustness of the initial study results. These analyses tested the...
Results

Among 25,629 patients with methylphenidate prescriptions, 19 had attempted suicide before the observation period and were therefore removed from the analysis, as per protocol. One hundred fifty-four patients had their first recorded suicide attempt within the observation period (eFigure 1 in the Supplement); of these, 111 (72.1%) were male and 43 (27.9%) were female. The mean (SD) age at commencement of observation was 7.15 (2.19) years (range, 6.0-16.47 years), and the mean duration of follow-up per participant was 12.15 (2.5-60) years. Mean methylphenidate exposure was 2.22 (2.33) years per participant. The median length of each prescription was 70 days (IQR, 20-70 days; range, 1-1023 days), and the median length of any antidepressant or antipsychotic medications was 70 days (IQR, 20-70 days; range, 1-1023 days). Male patients had a mean age at commencement of observation of 7.13 (2.05) years (range, 2.5-60) and 71 (1-838) days (IQR, 15-35 days) and female patients had a mean age at commencement of observation of 7.20 (2.54) years (range, 5-60) and 56 (1-1023) days (IQR, 15-35 days). Patients with a diagnosis of substance misuse/dependence had a mean age of 7.15 (2.19) years (range, 6.0-16.47 years) and the mean dura-
tion of any antidepressant or antipsychotic medications was 70 days (IQR, 20-70 days; range, 1-1023 days), and the mean length of prescription was 70 days (IQR, 20-70 days; range, 1-1023 days).

The analysis indicated some association between the decision to start methylphenidate treatment and suicide attempts (Table 3). After age and season were adjusted, an increased risk of suicide attempts was detected during the 90-day period before methylphenidate initiation (IRR, 6.55; 95% CI, 3.37-12.72). The IRR remained elevated during the first 90 days of methylphenidate treatment (IRR, 3.91; 95% CI, 1.62-9.42) before returning to baseline levels during prolonged treatment (IRR, 1.35; 95% CI, 0.30-2.59) (Table 3). A direct comparison between the risk of suicide attempts during the pre-exposure period and the methylphenidate treatment period showed that the corresponding risk was not increased during the first 90 days of methylphenidate treatment (IRR, 0.78; 95% CI, 0.26-2.35). However, a 72% lower risk was found in the subsequent period of methylphenidate treatment (IRR, 0.28; 95% CI, 0.08-0.94) compared with the pre-exposure period. Further analysis using nonparametric, spline-based SCCS showed that the risk of suicide attempts increased significantly before the initiation of methylphenidate treatment and reached a peak within 100 days before methylphenidate treatment (Figure 2). The age- and sex-stratified results showed a similar pattern to the overall analysis (eTable 3 in the Supplement). Post hoc analysis revealed that an increased risk of any
Risk of Suicidal Events With Methylphenidate Treatment

Table 3. Results From the Self-Controlled Case Series Analyses

<table>
<thead>
<tr>
<th>Risk Window</th>
<th>Adjusted IRR (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suicide Attempt (n = 154)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d Before 1st methylphenidate treatment</td>
<td>6.55 (3.37-12.72)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>First 90 d with methylphenidate treatment</td>
<td>3.91 (1.62-9.42)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Subsequent methylphenidate treatment</td>
<td>1.35 (0.77-2.38)</td>
<td>.30</td>
</tr>
<tr>
<td>Sensitivity Analyses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-mo Age band (n = 154)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d Before 1st methylphenidate treatment</td>
<td>5.36 (2.81-10.23)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>First 90 d with methylphenidate treatment</td>
<td>4.04 (1.87-8.75)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Subsequent methylphenidate treatment</td>
<td>1.44 (0.88-2.36)</td>
<td>.15</td>
</tr>
<tr>
<td>Patients with &gt;10 wk methylphenidate exposure (n = 113)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d Before 1st methylphenidate treatment</td>
<td>5.05 (2.04-12.48)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>First 90 d with methylphenidate treatment</td>
<td>3.38 (1.15-9.89)</td>
<td>.03</td>
</tr>
<tr>
<td>Subsequent methylphenidate treatment</td>
<td>1.38 (0.77-2.46)</td>
<td>.28</td>
</tr>
<tr>
<td>Censor by antidepressants/antipsychotics (n = 154)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d Before 1st methylphenidate treatment</td>
<td>8.08 (3.88-16.85)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>First 90 d with methylphenidate treatment</td>
<td>5.79 (2.28-14.73)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Subsequent methylphenidate treatment</td>
<td>1.14 (0.56-2.33)</td>
<td>.72</td>
</tr>
<tr>
<td>Remove patients with substance dependence (n = 114)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d Before 1st methylphenidate treatment</td>
<td>6.91 (3.44-13.87)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>First 90 d with methylphenidate treatment</td>
<td>3.69 (1.42-9.6)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Subsequent methylphenidate treatment</td>
<td>1.42 (0.77-2.61)</td>
<td>.26</td>
</tr>
<tr>
<td>Remove cases with event on the 1st day of treatment (n = 137)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d Before 1st methylphenidate treatment</td>
<td>5.54 (2.72-11.29)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>First 90 d with methylphenidate treatment</td>
<td>3.76 (1.56-9.05)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Subsequent methylphenidate treatment</td>
<td>1.32 (0.75-2.33)</td>
<td>.33</td>
</tr>
<tr>
<td>Start of observation at January 1, 2001; the 6th birthday of the patient; the first observed date of ADHD diagnosis; or first date of methylphenidate treatment, whichever occurred last (n = 126)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d Before 1st methylphenidate treatment</td>
<td>7.28 (3.22-16.5)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>First 90 d with methylphenidate treatment</td>
<td>3.65 (1.45-9.18)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Subsequent methylphenidate treatment</td>
<td>1.25 (0.69-2.28)</td>
<td>.46</td>
</tr>
<tr>
<td>Incident methylphenidate users only (n = 140)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d Before 1st methylphenidate treatment</td>
<td>6.57 (3.37-12.8)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>First 90 d with methylphenidate treatment</td>
<td>4.02 (1.66-9.73)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Subsequent methylphenidate treatment</td>
<td>1.32 (0.73-2.4)</td>
<td>.36</td>
</tr>
</tbody>
</table>

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; IRR, incidence rate ratio.

Discussion

In this population-based, retrospective study, the incidence of methylphenidate-related suicide attempts demonstrated a 6.5-fold and 4-fold elevation during the 90-day periods before and after the start of treatment, respectively. This finding suggests that the decision to start methylphenidate treatment follows the period of increasing risk for suicide attempts, with the risk remaining elevated and then beginning to fall after initiation of methylphenidate. The most parsimonious interpretation of this pattern of temporal association is that the observed increased risk of suicide attempts is not due to methylphenidate but precedes it, perhaps reflecting changes in behavioral and mental health symptoms or associated impairment that lead to a medical consultation, which in turn may contribute to the decision to prescribe methylphenidate. This hypothesis fits with the finding that the incidence of suicide attempts just after treatment initiation was comparable to that just before it, while after more than 90 days of methylphenidate use, the incidence was similar to that during the baseline period. In addition, the spline-based SCCS analysis showed a decreasing incidence of suicide attempts on the initiation of methylphenidate treatment. However, our results cannot be interpreted as demonstrating that methylphenidate has an immediate effect on lowering the risk of suicide attempts. The increased risk of suicide attempts before treatment may have been missed in a classic cohort study in which patients with psychiatric disorder was detected during the 90-day period before methylphenidate initiation (IRR, 22.14; 95% CI, 21.31-22.99). The risk remained elevated during the first 90 days of methylphenidate treatment (IRR, 9.40; 95% CI, 8.94-9.88) and during prolonged treatment (IRR, 1.53; 95% CI, 1.44-1.62) (eTable 4 in the Supplement). The additional sensitivity analyses did not change this general picture of results (eFigures 3-5 in the Supplement and Table 3).

Figure 2. Results From the Spline-Based Self-controlled Case Series Analysis

Incidence rate ratio (IRR) of suicide attempts throughout the time before and after methylphenidate exposure. The solid line is the estimated IRR, the dashed lines indicate the 95% CI, and the blue dashed line indicates baseline IRR.
either events or exposures before the commencement of the study are usually excluded. To our knowledge, this is the first study investigating the risk of suicide attempts before and after the start of methylphenidate treatment. The study results thus provide new evidence with which to interpret reports of an elevated risk of suicide attempts after initiation of methylphenidate treatment.

Several factors may explain why the initiation of methylphenidate treatment tends to coincide with the times of increased risk of suicide attempts. The initiation of new medication often occurs at a time of specific concerns about patients’ health. Patients with ADHD are at higher risk of suicide-related events. The decision to start treatment with methylphenidate may be a response to changes in behavioral or related psychiatric problems. These problems could be transient psychiatric disorders with ADHD or clinical observation in the period leading to initiation of methylphenidate. It is also well recognized that patients with ADHD are prone to cognitive, emotional, and behavioral comorbidities, for example, depression or disruptive behavioral disorders. These comorbidities may increase the likelihood of suicide attempts, which may consequently increase both the likelihood of medical and psychiatric consultations and receiving a methylphenidate prescription. This position is further supported by the post hoc analysis that found an increased risk of other psychiatric disorders before methylphenidate initiation. A previous study investigating the association between antidepressant medication and suicide also found the peak incidence of suicide attempts to be immediately before initiation of an antidepressant, suggesting that the attempt was a precipitant for initiation of antidepressant treatment. Only 2 patients in our sample died within the study period, and neither of them was receiving methylphenidate treatment at the time of death. Furthermore, the cause of death was not recorded as suicide. Therefore, in our cohort, death by suicide while receiving methylphenidate treatment is a rare outcome.

The suicidal ideation that precedes a suicide attempt may not be an acute event; patients with suicidal ideation may not carry out the attempt immediately. Therefore, there may be a time lag between the beginning of suicidal ideation and the suicide attempt event. This lag could possibly contribute to the increased risk during the first 90 days of methylphenidate treatment (IRR, 3.91; 95% CI, 1.62-9.42). Chen et al assumed the risk of suicidal behavior to be constant in nontreatment periods. However, in the present study, we found an increased risk of suicide attempts before the initiation of treatment. This finding suggests, therefore, that the estimate of risk derived by Chen et al may need to be reevaluated.

**Limitations**

There are a number of limitations to our study. First, CDARS does not have linkage to data from private medical practitioners. However, in HK, the public sector is the main provider of specialist care and there are very few private child and adolescent psychiatrists. As a consequence, the vast majority of patients receiving methylphenidate are likely to have been included in this study, and our sample should be highly representative of the HK population. In addition, our cohort included only clinically referred patients who had sufficiently severe ADHD symptoms and/or impairment to have received methylphenidate treatment. Therefore, our cohort may have a higher baseline risk compared with nonmedicated patients. However, since we applied an SCCS design, individual baseline risk does not affect our study results and conclusion. Second, CDARS provides data on drug prescriptions, but not on adherence, which may lead to misclassification of exposure periods. Third, because we had a comparatively long follow-up time, other time-varying confounding factors may affect the study results. Therefore, we conducted various sensitivity analyses to explore the potential effects of nonadherence and other confounding factors, and the results were consistent.

**Conclusions**

The incidence of suicide attempts peaked before the start of methylphenidate treatment, remained high immediately after the start of methylphenidate treatment, and declined during continuation of treatment. Our data, therefore, do not support a causal association between methylphenidate treatment and suicide attempts.
Pharmacy, University College Cork, Cork, Ireland (McCarthy); Department of Paediatrics and Addiction Medicine, University Hospital Erlangen, Erlangen, Germany (Neubert); Janssen Research & Development, LLC, Titusville, New Jersey (Schuermie); Department of Psychology, University of Southampton, Southampton, England (Sonuga-Barke, Kovshoff); Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboudumc, and Karakter Child and Adolescent Psychiatry, Nijmegen, the Netherlands (Buitelaar); Department of Biomedical Sciences, Section Of Neuroscience and Clinical Pharmacology, University of Cagliari, and Child and Adolescent Neuroscience Unit, G. Brozut Hospital Trust, Cagliari, Italy (Canucci, Zuddas); Vadaskert Child and Adolescent Psychiatric Hospital, Budapest, Hungary (Garas, Nagy); Tayside Clinical Trials Unit, University of Dundee, Dundee, Scotland (Inglis); Child Neuropsychology Section, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Clinics Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany (Konrad); Evelina London Children’s Hospital, London, England (Rosenthal); Research Department of Practice and Policy, University College London School of Pharmacy, London, England (Wong).

Author Contributions: Mr Man and Prof Wong had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Man, Hollis, Liddle, Banaschewski, Neubert, Ip, Schuermie, Zuddas, Konrad, Wong.

Acquisition, analysis, or interpretation of data: Man, Coghill, Chan, Lau, Hollis, Banaschewski, McCarthy, Sayal, Ip, Schuermie, Strunkboom, Sonuga-Barke, Buitelaar, Carucci, Zuddas, Kovshoff, Garas, Nagy, Inglis, Häge, Rosenthal, Wong.

Drafting of the manuscript: Man, Chan, Hollis, Liddle, McCarthy, Sonuga-Barke, Garas, Nagy.

Critical revision of the manuscript for important intellectual content: Man, Coghill, Chan, Lau, Hollis, Banaschewski, McCarthy, Neubert, Sayal, Ip, Schuermie, Strunkboom, Buitelaar, Carucci, Zuddas, Kovshoff, Garas, Nagy, Inglis, Konrad, Häge, Rosenthal, Wong.

Statistical analysis: Man, Chan, Lau, Hollis, Schuermie.

Obtained funding: Coghill, Hollis, Neubert, Buitelaar, Garas, Konrad, Wong.

Administrative, technical, or material support: Man, Hollis, Ip, Nagy.


Conflict of Interest Disclosures: The research leading to these results received financial support from the European Community’s 7th Framework Programme. Dr Coghill received grants and personal fees from Shire Pharmaceutical Company and Vifor Pharma; personal fees from Janssen-Cilag, Eli Lilly, Novartis, Flynn Pharma, Medice Arzneimittel Pütter, and Oxford University Press outside the submitted work. Dr Chan received grants from Bristol-Myers Squibb, Janssen, a division of Johnson and Johnson; the Research Grants Council of Hong Kong; and the Health and Medical Research Fund of Hong Kong outside the submitted work. Prof Hollis was chair of the National Institute for Health and Clinical Excellence (NICE) psychosis and schizophrenia in children and young people ADHD Guideline Group and has been an investigator on a research grant from Shire Pharmaceutical Company to the University of Nottingham. Prof Banaschewski received personal fees from Medice Arzneimittel Pütter outside the submitted work and served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Medice Arzneimittel Pütter, Novartis, Oxford Outcomes, PCM Scientific, Shire Pharmaceutical Company, and Vifor Pharma. Dr McCarthy received grants from Shire Pharmaceutical Company. Dr Schuermie is a full-time employee of Janssen Research & Development and shareholder of Johnson & Johnson. Prof Strunkboom is leading a research group that received grants for specific postauthorization safety projects from Novartis, Boehringer, GSK, and Servier, with none related to the topic of the present study. Prof Buitelaar has served as a consultant to and member of advisory boards and/or speakers’ bureaus for Janssen Cilag BV, Eli Lilly, Lundbeck, Shire Pharmaceutical Company, Roche, Medice Arzneimittel Pütter, Novartis, and Servier and received research support from Roche and Vifor Pharma. Dr Carucci collaborated within projects from the European Union (7th Framework Programme), has received personal fees from Shire Pharmaceutical Company, and collaborated as a subinvestigator in clinical trials sponsored by Shire Pharmaceutical Company and Lundbeck. Prof Zuddas has served on the advisory boards of Shire Pharmaceutical Company, AstraZeneca, EcoPharma and Angelini; has received research support from Shire Pharmaceutical Company, Vifor Pharma, Roche, Lundbeck, the European Union (7th Framework Programme), and the Sardinian Health Secretariat; served on data safety monitoring boards of Otsuka and Lundbeck; and has received royalties from Gentium OS and Oxford University Press. Dr Nagy has been a member of the advisory board of Eli Lilly and has received a research grant from Shire Pharmaceutical Company. Prof Konrad received speaker fees from Shire Pharmaceutical Company and was part of an investigator-initiated trial from Vifor Pharma outside the submitted work. Dr Häge served in an advisory or consultancy role for Shire Pharmaceutical Company. Prof Wong received grants from European Union 7th Framework Programme during the conduct of the study; grants from Shire Pharmaceutical Company, Janssen-Cilag, Eli Lilly, and Pfizer Inc outside the submitted work; was a member of the NICE ADHD Guideline Group and the British Association for Psychopharmacology ADHD guideline group; and acted as an advisor to Shire Pharmaceutical Company. No other conflicts were reported.

Funding/Support: The Attention Deficit/Hyperactivity Disorder Drugs Use Chronic Effects project, European Community’s 7th Framework Programme project number 260576, partially funded this project.

Role of the Funder/Sponsor: The funder had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the Hong Kong Hospital Authority for access to the data from CDARS for research purposes.

REFERENCES


34. Hospital Authority Head Office IT Department. Clinical Data Analysis & Reporting System (CDARS) User’s Manual: 2.0 ed. Hong Kong, Hong Hospital Authority; 2003:3.


